(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...
Novo Nordisk is working on a new obesity drug that could help patients shed more than any other weight-loss drug on the ...
With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists ...
SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
A new Dublin-headquartered company for rare diseases, Oranda Therapeutics, is seeking to raise €35 million in an early-stage ...